Morningstar Investor users sign in here.

Company Profile

  • Business description

    Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

  • Contact

    675 West Kendall Street
    Henri A. Termeer Square
    Cambridge MA 02142
    USA

    T: +1 617 551-8200

    E: INVESTORS@ALNYLAM.COM

    https://www.alnylam.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    2,100

Stocks News & Analysis

stocks

The secrets of Australia’s Berkshire Hathaway

Washington H. Soul Pattinson is an ASX top 50 stock with one of the best investment track records this country has seen. Yet, most Australians haven’t heard of it, and the company seems to prefer it that way.
stocks

Have some of the ASX 200's worst performers fallen too far?

These four stocks have had an awful twelve months. Morningstar's analysts weigh in on whether they offer good value yet. 
stocks

Private equity bid dramatically undervalues ASX listed share

We believe the bid is an attempt to capitalise on share price weakness. 

Markets

Index
Last price
Change
% Change
All Ordinaries 8,002.50 39.40 0.49%
CAC 40 7,708.02 156.68 -1.99%
DAX 40 18,265.68 365.18 -1.96%
Dow JONES (US) 38,647.10 65.11 -0.17%
FTSE 100 8,163.67 51.81 -0.63%
HKSE 18,112.63 174.79 0.97%
NASDAQ 17,667.56 59.13 0.34%
Nikkei 225 38,720.47 156.24 -0.40%
NZX 50 Index 11,872.64 130.76 1.11%
S&P 500 5,433.74 12.71 0.23%
S&P/ASX 200 7,749.70 34.20 0.44%
SSE Composite Index 3,028.92 8.55 -0.28%

Market Movers

Name
Last price
Change
% Change
Sigma Healthcare Ltd SIG 1.16 0.05 -3.73%
Peninsula Energy Ltd PEN 0.10 0.00 4.17%
South32 Ltd S32 3.64 0.00 0.00%
Pilbara Minerals Ltd PLS 3.32 0.09 -2.64%
Telstra Group Ltd TLS 3.53 0.01 0.28%
Core Lithium Ltd CXO 0.09 0.00 -1.05%
Red 5 Ltd RED 0.44 0.01 1.15%
Mirvac Group MGR 1.93 0.03 1.58%
TerraCom Ltd TER 0.22 0.01 -2.27%
Imugene Ltd IMU 0.06 0.00 1.75%